Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Johnson and Johnson
Mallinckrodt
AstraZeneca
Dow

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,740,669

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,740,669 protect, and when does it expire?

Patent 6,740,669 protects BANZEL and is included in two NDAs.

Protection for BANZEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighty-seven patent family members in thirty-four countries.

Summary for Patent: 6,740,669
Title: Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
Abstract:The invention relates to the novel modification A or A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula ##STR1## its use and pharmaceutical preparations comprising this crystal modification.
Inventor(s): Portmann; Robert (Pratteln, CH), Hofmeier; Urs Christoph (St. Pantaleon, CH), Burkhard; Andreas (Basel, CH), Scherrer; Walter (Rheinfelden, CH), Szelagiewicz; Martin (Munchenstein, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:09/125,329
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,740,669
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 6,740,669

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc BANZEL rufinamide SUSPENSION;ORAL 201367-001 Mar 3, 2011 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-001 Nov 14, 2008 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-002 Nov 14, 2008 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-003 Nov 14, 2008 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,740,669

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland1404/97Jun 10, 1997
PCT Information
PCT FiledJune 08, 1998PCT Application Number:PCT/EP98/03427
PCT Publication Date:December 17, 1998PCT Publication Number: WO98/56772

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
McKesson
Harvard Business School
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.